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Abstract 
Background: Alzheimer’s disease (AD) biomarkers are urgently needed for 
both early and accurate diagnosis, and prediction of disease progression. 
Past research has studied blood-based proteins as potential AD biomarkers, 
revealing many candidate proteins. To date only limited effort has been made 
to investigate the disease specificity of AD candidate proteins and whether 
these proteins are also involved in other neurodegenerative or psychiatric 
conditions. 
 
Objective: This review seeks to determine if blood-based AD candidate 
protein biomarkers are disease specific. 
 
Methods: A two-stage systematic literature search was conducted. Firstly, the 
most consistently identified AD protein biomarkers in blood were determined 
from a list of published discovery or panel-based (>100 proteins) blood 
proteomics studies in AD. Secondly, an online database search was 
conducted using the 10 most consistently identified proteins to determine if 
they were involved in other brain disorders, namely frontotemporal lobe 
dementia (FTD), vascular dementia (VD), Lewy Body disease (LBD), 
Parkinson’s disease (PD), schizophrenia (SCZ), depression (DEP) and autism 
(AUT). 
 
Results: Among the reviewed candidate proteins, plasma protease C1 
inhibitor, pancreatic prohormone and fibrinogen γ chain were found to have 
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the least evidence for non-specificity to AD. All other candidates were found to 
be affected by other brain disorders 
 
Conclusion: Since we found evidence that the majority of AD candidate 
proteins might also be involved in other brain disorders more research into 
diseases specificity of AD protein biomarkers is required. 
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1 Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia affecting up 
to 6% of the population aged over 65. It is clinically manifested by progressive 
cognitive decline such as memory loss and executive dysfunction, as well as 
psychiatric symptoms and behavioral disturbances [1]. 
 
The pathophysiology of AD remains poorly understood. However, it is 
characterized by neuronal degeneration and brain shrinkage, particularly in 
the hippocampus and mesial temporal lobe structures [2]. At the microscopic 
level, two main pathological features predominate. The deposition of amyloid 
β and hyperphosphorylated tau proteins leads to the formation of amyloid 
plaques and neurofibrillary tangles in brain tissue [3]. 
 
Though several methods have been developed to alleviate the symptoms of 
AD, no therapies have been developed that can modify the course of the 
disease [4]. This stems not only from a lack of a detailed understanding of the 
pathophysiological processes underpinning the disease, but also an inability 
to diagnose patients both accurately and early. It has been estimated that 
about two-thirds of dementia patients go undiagnosed [5], and that by the time 
of diagnosis AD pathology has been developing for ~20 years [6]. Thus 
biomarkers that can diagnose AD accurately and early are urgently needed. 
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Presently, a definitive diagnosis of AD can only be made postmortem. Clinical 
diagnosis of AD remains difficult especially to non-specialists. Current 
methods for diagnosing AD involve a detailed history and neuropsychological 
testing to establish the presence of dementia. Other investigations must then 
be conducted to distinguish AD from other forms of dementias such as VD, 
FTD and LBD [1,7]. 
 
Protein biomarkers in the cerebrospinal fluid (CSF) such as a reduced 
amyloid β or an elevated tau concentration have been used with a fair degree 
of accuracy to diagnose early AD [8]. Yet a lumbar puncture remains a 
relatively invasive procedure and may not be practical for conducting large-
scale studies on AD. Neuroimaging methods such as positron emission 
tomography (PET) to measure amyloid in the brain or magnetic resonance 
imaging (MRI) to measure atrophy of medial temporal structures have also 
proved useful [9,10]. However, PET is expensive and not readily available in 
many places, while brain atrophy, as measured by MRI, requires specialized 
facilities and is less specific to AD. The use of blood-based biomarkers is 
therefore an attractive alternative given the accessibility of blood [11]. 
 
The search for blood-based biomarkers for AD has thus far yielded promising 
results. Recently, Kiddle et al.  [11] conducted a review summarizing the most 
frequently reported AD biomarkers in blood. Kiddle et al. [11] showed that 163 
blood protein markers of AD have been found from 21 literature studies, of 
which only 33% of proteins have been seen in independent studies. Despite 
this, four proteins were found to be associated with AD in 5 independent 
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cohorts. However, thus far no attempt has been made to determine whether 
these proteins identified are also involved in other dementia types or mental 
illnesses. It is thus vital to determine whether the protein biomarkers identified 
in literature are AD specific or simply indicative of a general brain disorder. 
 
This literature review seeks to build on the work of Kiddle et al. [11] by 
attempting to establish if identified potential blood-based protein biomarkers 
for AD are involved in other neurodegenerative or psychiatric disorders.  
 
2 Methods 
This systematic review was split into two tasks: (1) compilation of an up to 
date list of potential blood-based protein biomarkers of AD and (2) compilation 
of literature evidence for non-specificity of the most promising markers. For 
the second task the biomarkers most consistently associated with AD were 
identified and a literature search was conducted to determine if these proteins 
were identified as potential biomarkers in other brain disorders.  
 
2.1 AD	  candidate	  proteins	  
For this study the review criteria of Kiddle et al.  [11] were repeated to bring it 
up to date. This consisted of identifying studies of blood protein biomarkers of 
AD-related phenotypes, including studies of plasma, serum and leucocyte 
proteins. The requirements for inclusion as a biomarker were that a protein 
had to have been identified in a discovery study, rather than a candidate 
based study. Exceptions were made for panel-based studies that included 
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more than 100 candidate proteins as these were considered to be broad 
enough to exclude bias.  
 
As in Kiddle et al. [11], studies were identified from two recent reviews on AD-
related blood protein biomarkers by Lista et al.  [12] and Zurbig and Jahn [13]. 
In addition, studies that used the Myriad Rules Based Medicine (RBM) Human 
Discovery Multi-Analyte Profile (MAP), several of which were published after 
the two reviews, were also included. Finally the PubMed search term 
‘Alzheimer blood protein discovery’ was used to identify additional studies. 
The proteins were then ranked according to the extent in which they had been 
replicated in independent research cohorts.  
 
 
2.2 AD	  candidate	  proteins	  in	  other	  brain	  disorders	  
The top 10 AD-related proteins were identified from the compiled list and a 
systematic literature search was conducted to determine if these protein 
biomarkers were also involved in other brain disorders, namely: FTD, VD, 
LBD, PD, SCZ, DEP and AUT. 
 
An Ovid search strategy was devised using MEDLINE, PsychInfo and 
Embase. The search strategy utilized a combination of Medical Subject 
Heading (MeSH) terms, key words and Boolean operators. The 10 identified 
proteins were mapped to the appropriate MeSH terms on each of the 
databases with keywords used when necessary. The selected terms were 
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then combined with the appropriate MeSH terms for the respective brain 
disorders using the Boolean operator ‘And’.  
 
The papers obtained during the search were then screened through additional 
eligibility criteria. Since this was an exploratory study, fairly broad criteria were 
used to determine the suitability of papers. Papers deemed suitable had to be 
blood-based studies examining the association of a difference in quantity of 
any of the searched proteins with any of the searched diseases. A protein was 
deemed a potential biomarker if this was explicitly stated in the paper, or if the 
reviewed study found any statistically significant difference in the quantity of 
the blood-based protein for the respective diseases. Papers explicitly showing 
that there was no statistically significant difference in protein quantity were 
also included for comparison. Only papers written in English and published 
after 1990 were included. Papers investigating genotypes that could 
potentially affect protein levels, as well as studies that investigated changes in 
the characteristics of the proteins such as glycosylation were excluded. 
3 Results 
3.1 AD	  candidate	  proteins 
In addition to the 21 papers identified by Kiddle et al. [11], two recent studies 
by Burnham et al.  [14] and Sattlecker et al. [15] were added, bringing the total 
number of discovery or panel-based proteomics studies to 23 in total [14-36]. 
These 23 papers, utilizing 18 independent research cohorts, identified a total 
of 179 potential blood-based protein biomarkers (Supplementary Table 1). 
The proteins were ranked in order of the number of independent cohorts that 
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they had been associated with, and the top 10 proteins identified for 
comparison with other brain disorders (Table 1). These proteins included all 
markers associated with an AD-related phenotype in at least four independent 
cohorts. 
 
Of the 10 proteins, five proteins - pancreatic prohormone, apolipoprotein E, 
alpha-2-macroglobulin, complement C3 and alpha-1-antitrypsin - were found 
to be associated with AD phenotypes in five independent cohorts. The other 
five proteins - complement factor H, plasma protease C1 inhibitor, serum 
amyloid P component, fibrinogen γ chain, and serum albumin - were found to 
be associated with AD phenotypes in four independent cohorts. All the 
proteins were identified in at least four separate papers with pancreatic 
prohormone being identified in the most papers at seven.  
 
3.2 AD	  candidate	  proteins	  in	  other	  brain	  disorders	  
The initial literature search yielded a total of 3,223 papers across all three 
databases. Sixty-two papers were then identified through manually searching 
the abstracts for papers that conducted blood proteomic studies in the 
relevant conditions. This was eventually narrowed down to 29 papers after 
closer review and exclusion of duplicate papers from the different databases 
[37-65]. (Figure 1) 
 
Of the 29 papers, 12 of them studied DEP, nine studied SCZ, eight studied 
PD and a single paper studied AUT. One paper, Domenici et al. [60], studied 
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both SCZ and DEP. No papers could be found on any of the dementia types 
such as VD, FTD and LBD. (Table 2) 
 
Serum albumin was identified in 14 papers followed by complement C3 in 
nine papers and alpha-2-macroglobulin in seven papers. Conversely, plasma 
protease C1 inhibitor was not identified in any papers, while pancreatic 
prohormone and fibrinogen γ chain were each only identified in a single 
paper. 
 
When we consider the relationship between the proteins and other conditions, 
it can be seen that two proteins - plasma protease C1 inhibitor and fibrinogen 
γ chain – have not been found to associate with any of the other diseases. By 
contrast, the other eight blood protein markers of AD have been related to at 
least one other brain disorder. Pancreatic prohormone and complement factor 
H were found to be associated with PD. Apolipoprotein E and serum amyloid 
P were associated with both PD and SCZ. Alpha-2-macroglobulin, 
complement C3 and serum albumin were found to be associated with PD, 
SCZ and DEP. Finally, alpha-1-antitrypsin was associated with PD, SCZ, DEP 
and AUT (Table 1). 
4 Discussion 
The results from our systematic literature review suggest that a majority of 
these candidate proteins are also involved in other brain disorders. However, 
three candidate proteins, plasma protease C1 inhibitor, fibrinogen γ chain and 
pancreatic prohormone might be AD specific biomarkers as their association 
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with AD is relatively well replicated and there appears to be very little 
evidence of association between their level in blood and other brain disorders. 
No studies were found on protease C1 inhibitor while the only study that 
tested for fibrinogen γ chain found no significant difference in quantity for PD 
[52]. 
 
Raised levels of pancreatic prohormone were found to be present in patients 
with PD. However, this was only shown in a single paper that studied the 
post-prandial (i.e. after meal) secretion of pancreatic prohormone and not a 
generalized increase in blood levels of the protein [47]. In contrast it was 
standard practice for subjects to undergo overnight fasting before blood 
sampling for the AD studies reviewed. Given this and the fact that blood 
pancreatic prohormone levels have been found to be associated with AD in 
the most studies, its feasibility as a potential biomarker of AD remains 
relatively strong. 
 
Overall, there were a greater number of papers linking the AD candidate 
proteins to PD and SCZ, relative to the other disorders reviewed. It is 
noteworthy that AD and PD are both old age psychiatric disorders, and that 
psychotic symptoms occur in both AD and SCZ [66]. A further similarity 
between AD and SCZ is atrophy of the medial temporal lobe [66]. Given the 
findings of this review, it is plausible that some of the candidate markers of AD 
are indicative of general medial temporal lobe atrophy. 
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It should be noted that alpha-2-macroglobulin, complement C3, alpha-1-
antitrypsin, complement factor H, serum amyloid P and serum albumin can be 
considered as acute-phase proteins. These are a class of protein that 
characteristically increase or decrease in plasma concentrations as part of an 
inflammatory response. Indeed many of the studies found were investigations 
into the response of acute-phase proteins in the various neurodegenerative 
and psychiatric conditions [50,55,59,61,64]. Thus the change in concentration 
of these proteins found in the various conditions could be a reflection of 
underlying inflammatory processes that are associated with the conditions. 
Therefore, acute-phase proteins are less likely to be AD specific. 
 
Serum albumin is the protein that by far produced the most search results 
This is unsurprising as it is the most abundant protein in blood and so is highly 
studied. Studies have found serum albumin to be lowered in both SCZ 
[38,39,54] and DEP [40-45,61]. In PD, Goldknopf et al.  [56] and Usha et al.  
[53] showed serum albumin to be decreased.  However, Jimenez-Jimenez et 
al.  [37] found no difference in serum albumin concentration while Alberio et 
al.  [52] showed an increase in concentration of serum albumin in PD. Serum 
albumin, in addition to being an acute-phase protein, is also generally used as 
a nutritional marker [43]. Thus, the decrease in serum albumin levels, which is 
found in most of the studies, might be attributed to malnutrition due to a lack 
of self-care found in patients with neurodegenerative or psychiatric conditions. 
For this reason serum albumin is unlikely to be a marker specific to AD. 
A number of proteins did not show clear directions in their associations with 
the various conditions with the results of different studies contradicting each 
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other. For example, apolipoprotein E was found to be elevated in PD by Ikeda 
et al. [65], but lowered in Alberio et al.  [52] and Goldknopf et al. [56]. This could 
be due to small sample sizes, cohort heterogeneity and differences in 
proteomic approaches, and will need further validation. However, there are 
some proteins that show consistent associations in certain conditions. Serum 
albumin, as mentioned above, has been found by all papers reviewed to be 
consistently lowered in SCZ [38,39,54] and DEP [40-45,61]. Pancreatic 
prohormone has also been shown in papers to be consistently raised in AD 
[15-20,67]. This inconsistency in results among the majority of proteins, as well 
as their association with other conditions, creates a rather unclear picture and 
lowers their potential to be used as biomarkers of AD. 
The differences in the proteomic methods used to quantify the proteins across 
the reviewed studies was a complication faced in this review. Methods ranged 
from staining with bromocresol green dye for serum albumin to more complex 
methods such as 2-D gel electrophoresis, nephelometry, ELISA and 
antibody/aptamer microarray technology. This may mean that some of the 
candidate protein markers have never been appropriately tested for 
association with the other brain disorders. While older studies were limited in 
their protein profiling, restricted to small groups of proteins such as 
inflammatory markers or anti-oxidant content, later studies with the new 
human MAP technology were able to sample a much more comprehensive list 
of proteins, allowing potential biomarkers to be discovered in a more unbiased 
fashion.  
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Surprisingly, no papers were discovered on any of the non-AD dementia types 
searched, namely FTD, VD and LBD. This is possibly due to the relatively low 
level of blood biomarker research performed for these conditions. However, a 
greater number of studies in CSF have been performed for these disorders. 
For example, one of the most replicated blood protein markers of AD is alpha-
1-antitrypsin, whose level in CSF has been shown not to be significantly 
different between AD and LBD subjects [68]. Blood levels of transthyretin has 
been shown to be associated with AD-related phenotypes in 2 independent 
cohorts. Another CSF study has shown that CSF levels of transthyretin differ 
in both AD and PD subjects relative to controls [69]. Both of these CSF 
studies demonstrate non-specificity of these markers in a tissue that 
surrounds the brain, which increases the chances that these proteins will be 
less specific blood-based marker of AD.  
Another reason for the lack of relevant papers found for other dementia types 
is the proteins we investigated, i.e. some of the less well-replicated blood-
based AD biomarkers have been related to these disorders. For example 
APOA1 has been shown to predict PD motor disease severity and age at 
onset [70]. The lack of diagnostic evidence to separate different dementia 
types might also be a factor for the lack of research done in this area. It is also 
noteworthy that some papers focused on dementias in general instead of 
splitting them into the different subtypes and were therefore excluded.  
While this review gives an idea of the current literature available with regards 
to AD blood protein biomarkers in other conditions, there are nonetheless 
certain limitations. Since the inclusion criteria for the review was kept fairly 
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broad in order to get a comprehensive impression of the amount of literature 
available for the chosen AD biomarkers, there is a lack of consistency in the 
methodology used in the different papers reviewed. This makes it difficult to 
compare papers with each other since there is a difference in criteria used to 
determine if blood proteins are elevated or lowered. 
The heterogeneity in the protocol and methodology of the studies could also 
potentially contribute to the inconsistency in the results. This can be seen 
even in the AD biomarkers where contradictory results in the direction of 
protein associations are seen. Watt et al.  [71] have shown that one source of 
variability in blood-based markers is the differences in pre-analytical 
methodologies with regard to blood collection, processing and storage.  
Another potential source of heterogeneity is the different disease stages 
investigated in the different studies. For example, of the 21 AD studies 
reviewed: 11 were case-control studies [16,17,21,24,28-33,36], 2 studied 
subjects with early to late AD symptoms [18,19], 2 studied AD drug efficacy 
[23,34], 2 studied pre-symptomatic subjects (based on eventual conversion or 
brain amyloid burden) [26,27], one studied early vs late stage AD symptoms 
(MCI vs AD), one studied AD progression [35] and one studied pre/post-
symptomatic subjects as well as AD progression [22]. Given the relative lack 
of replication studies across the disease stages, and the use of different 
proteomic techniques, disease-stage specific findings should not be over-
interpreted at this stage. This would be an interesting area for further study. 
The lack of studies found on a particular protein or disease might also not be 
reflective of a lack of association. Rather it might indicate a lack of research 
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conducted on a specific protein with a specific disease. It is possible that 
some proteins and diseases are just less researched and therefore would not 
be expected to yield as much search results. This paper attempted to take this 
factor into account by also including papers that explicitly mentioned if a 
particular protein was not found to have altered concentration in the blood. 
However, with the tendency for papers to only mention proteins with 
significant results, and for researchers to mostly publish positive results, it is 
possible that some of these negative findings might have been missed.  
This paper considered depression both as a psychiatric illness as well as a 
symptom. Therefore the trends seen in the various proteins for depression 
should be seen as indicative of depressive symptoms instead of a defined 
psychiatric illness such as major depressive disorder or dysthymia. A number 
of papers studied depression in relation with other comorbidities such as renal 
disease and therefore might not be indicative of the general population [41-
43]. 
There remain many avenues for future enquiry. Only the top 10 in a list of 179 
potential blood-based biomarkers were selected for further study in this 
review. This choice was made to focus on the most replicated proteins and 
also to make the review practical given that searches involving these 10 
proteins returned 3,223 studies. It might thus be appropriate to determine if 
any of the other AD-related proteins down the list are associated with other 
neurodegenerative or psychiatric conditions in future studies. It will also be 
interesting to see if the AD-related proteins are found in other 
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neurodegenerative disorders not studied in this review, such as Huntington’s 
disease or motor neuron disease.  
Of all the 29 papers reviewed, only three papers used human MAP 
technology, allowing the study of hundreds of proteins at once [57,58,60]. 
When this technology, and other high-throughput proteomics approaches 
such as SOMAscan [11,15], are applied more frequently in the study of 
various neurodegenerative and psychiatric conditions, it is likely that a clearer 
picture of potential protein biomarkers will be obtainable.  
It is also important to consider multi-variate approaches to studying the 
proteomics of various conditions. This review considered the association of 
individual proteins with the various conditions. However due to the multiplicity 
of factors involved in the pathophysiology of various brain disorders it is likely 
to be more helpful to consider patterns in groups of proteins instead of just 
single proteins in isolation. Employment of high-throughput proteomics 
approaches, such as MAP, is making this kind of study increasingly possible 
and it is likely that this will be the norm in the future.  
Finally, while this review was able to demonstrate the non-specificity of some 
protein markers of AD, larger cross-disorder studies using standardized pre-
analytical and proteomic approaches need to be performed to confirm and 
extend the findings of this review. At present cross-disorder studies have low 
sample size, for example Edvinsson used 80 subjects to show that plasma 
levels of neuropeptide Y were non-specfic between AD and FTD [72]. In fact 
for the large AD blood biomarker studies subjects are excluded if they have a 
non-AD dementia diagnosis. Large cross-disorder studies would allow the 
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specificity of AD markers to be assessed independently of literature biases 
and platform differences. This would enable greater accuracy in determining 
whether identified protein biomarkers are specific to AD or simply indicative of 
a generalized neurodegenerative state. 
5 Conclusion 
From this review it would appear that pancreatic prohormone, plasma 
protease C1 inhibitor and fibrinogen γ chain are the AD-related blood-based 
biomarkers that have the least evidence for association with other 
neurodegenerative and psychiatric conditions. Many of the other proteins 
however were found to be associated with other conditions, especially PD, 
SCZ and DEP. The direction of association between proteins was often found 
to be inconsistent, with contradictory evidence found between different 
studies.  
It is likely that more extensive proteomic studies need to be conducted before 
the association between blood-based protein biomarkers and various 
neurodegenerative and psychiatric conditions can be fully elucidated. 
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